Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.
- 1 March 1981
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 78 (3), 1680-1684
- https://doi.org/10.1073/pnas.78.3.1680
Abstract
The multiple systemic administration of multilamellar liposomes composed of phosphatidylserine and phosphatidylcholine (molar ratio 3:7) that contained water-soluble muramyl dipeptide (MDP) activated alveolar macrophages to become tumoricidal and eradicated established spontaneous pulmonary and lymph node metastases. Spontaneously metastasizing melanoma cells were injected into the footpads of mice. After 4-5 wk, the tumors were resected by a midfemoral amputation; 3 days later, twice-weekly injections of liposomes were initiated and continued for 4 wk. In some experiments the mice were killed 2 wk after the final treatment. Seventy-four percent of animals injected with liposomes containing MDP were free of visible metastases. In a separate life-span experiment, 60% of mice treated with liposome-encapsulated MDP were tumor-free 120 days after the last liposome treatment or 110 days after all control mice treated with free MDP or control liposome preparations had died of disseminated cancer. The systemic administration of liposomes containing MDP, or similar compounds that produce macrophage activation, may provide and additional useful approach to the therapeutic regimens currently used to eradicate cancer metastases.This publication has 31 references indexed in Scilit:
- Synthetic immunostimulants derived from the bacterial cell wallJournal of Medicinal Chemistry, 1980
- Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factorCellular Immunology, 1980
- The pathogenesis of cancer metastasisNature, 1980
- Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide.The Journal of Experimental Medicine, 1980
- The comparative effects of isoprinosine, levamisole, muramyl dipeptide and SM1213 on lymphocyte and macrophage proliferation and activation in vitroInternational Journal of Immunopharmacology, 1979
- Direct augmentation of cytolytic activity of tumor-derived macrophages and macrophage cell lines by muramyl dipeptideCellular Immunology, 1979
- Implications of immunological heterogeneity of tumoursNature, 1979
- Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouseInternational Journal of Immunopharmacology, 1979
- Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble componentsCellular Immunology, 1976
- Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivativesBiochemical and Biophysical Research Communications, 1974